Provided by Tiger Trade Technology Pte. Ltd.

GeneDx Holdings

87.07
+4.525.47%
Post-market: 87.070.00000.00%19:37 EDT
Volume:555.28K
Turnover:47.42M
Market Cap:2.58B
PE:-23.92
High:87.17
Open:83.71
Low:80.76
Close:82.55
52wk High:170.87
52wk Low:32.21
Shares:29.68M
Float Shares:19.02M
Volume Ratio:1.19
T/O Rate:2.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6399
EPS(LYR):-0.7339
ROE:-40.80%
ROA:-7.89%
PB:10.58
PE(LYR):-118.63

Loading ...

A Look At GeneDx Holdings (WGS) Valuation After Q1 2026 Reset And Securities Investigation

Simply Wall St.
·
May 18

GeneDx director Keith Meister reports $13.75 million Class A common share purchase

Reuters
·
May 16

Corvex’s Keith Meister buys $48.44 million GeneDx common shares

Reuters
·
May 12

Stock Track | GeneDx Holdings Plummets 5.57% Intraday as Alphabet Dissolves Stake

Stock Track
·
May 08

Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom

Reuters
·
May 08

Why Is GeneDx Stock Surging Thursday?

Benzinga Earnings
·
May 08

GeneDx Holdings Corp : Piper Sandler Cuts Target Price to $50 From $130

THOMSON REUTERS
·
May 07

If AI Reshapes Healthcare, These Three Stocks Could Lead

Simply Wall St.
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

Stock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut

Stock Track
·
May 05

GeneDx price target lowered to $85 from $153 at Craig-Hallum

TIPRANKS
·
May 05

Top Premarket Decliners

MT Newswires Live
·
May 05

Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025

GlobeNewswire
·
May 05

GeneDx Holdings Is Maintained at Buy by BTIG

Dow Jones
·
May 05

Piper Sandler Remains a Buy on GeneDx Holdings (WGS)

TIPRANKS
·
May 05

GeneDx Falls Premarket After Company Slashes '26 Rev View

Dow Jones
·
May 05

GeneDx Shares Slump 41.5% Premarket to $39.71 After Co Trims FY REV Outlook

THOMSON REUTERS
·
May 05

Stock Track | GeneDx Holdings Plunges 40% in Pre-Market After Q1 Revenue Miss and Drastic Full-Year Guidance Cut

Stock Track
·
May 05

U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi

Reuters
·
May 05

Stock Track | GeneDx Holdings Plunges 42.96% After-Hours on Q1 Revenue Miss and Drastic Full-Year Guidance Cut

Stock Track
·
May 05